

# MAJOR MILESTONE: U.S. Life Sciences Investments Top \$500B+



Pharmaceutical companies are continuing to invest big in America, **pledging more than \$582 billion** since 2025. The surge in American-based investment strengthens the future discovery and delivery of life-altering treatment for U.S. patients while benefiting a sector of the economy that America must continue to secure its position in as a world leader. The life science industry supports **more than 4.9 million jobs**, including **778K+ in California** as of 2022.

## IN CALIFORNIA



New facilities and expansions by **Gilead** in Foster City, **Amgen's** \$600 million R&D center in Thousand Oaks, **AstraZeneca's** research, development and cell therapy manufacturing in Tarzana, **Amphastar's** headquarters expansion in Rancho Cucamonga, and a new **Novartis** R&D hub in San Diego and manufacturing facility in Carlsbad



## Congress: Protect America's Position As the World Leader in Life Sciences. Oppose Importing Foreign Healthcare Policies & MFN Drug Pricing

Continued sector investment requires a policy environment that encourages innovation and protects American jobs. Global competitors, including China, are closing the gap.

Drug pricing policies like Most Favored Nation threaten America's biotech revolution.

**230+**

fewer new medicines over 10 years

**1.1 million**  
lost jobs

Surrender competitive edge to  
**China**

**Fail**

to lower patient costs or address the real drivers of rising healthcare costs

Stay up-to-date on the latest life sciences' investment announcements and state-specific industry impact at [weworkforhealth.org/investinamerica](http://weworkforhealth.org/investinamerica) and [weworkforhealth.org/in-the-states](http://weworkforhealth.org/in-the-states).

